Analyst Ryan Zimmerman from BTIG noted that while the proposal appears severe, it might lead to market consolidation. Despite the proposal's impact, Zimmerman maintains a buy rating on Organogenesis. MiMedx's CEO, Joe Capper, emphasized the company's commitment to advocating for market reform and expressed confidence in future growth prospects, projecting high single-digit revenue growth for the full year. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.